Somatostatin Receptor Ligand

Somatostatin Receptor Ligand

SCHEMBL3046327

CC(N)C(=O)NCC(=O)NC1CSSCC(C(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(Cc2ccccc2)NC(=O)C(C(C)O)NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccccc2)NC(=O)C(CC(N)=O)NC(=O)C(CCCCN)NC1=O

nearest known ligand 0.83

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SSTR1SSTR2SSTR3SSTR4SSTR5

The experimentally established mechanism targets of Somatostatin Receptor Ligand. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
SSTR4 known ✓ P31391 13/20 0.83
SSTR1 known ✓ P30872 11/20 0.83
SSTR2 known ✓ P30874 10/20 0.83
SSTR5 known ✓ P35346 10/20 0.83
SSTR3 known ✓ P32745 10/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Somatostatin Receptor Ligand SCHEMBL16186775 1.00 SSTR4 (0.83) SSTR4SSTR1SSTR2SSTR5SSTR3
SCHEMBL29368491 1.00 SSTR4 (0.83) SSTR4SSTR1SSTR2SSTR5SSTR3
Somatostatin SCHEMBL29350200 1.00 SSTR4 (0.83) SSTR4SSTR1SSTR2SSTR5SSTR3
Somatostatin Receptor Ligand SCHEMBL31432768 1.00 SSTR4 (0.83) SSTR4SSTR1SSTR2SSTR5SSTR3
Somatostatin Receptor Ligand SCHEMBL8482 1.00 SSTR4 (0.83) SSTR4SSTR1SSTR2SSTR5SSTR3
Somatostatin Receptor Ligand SCHEMBL29386529 1.00 SSTR4 (0.83) SSTR4SSTR1SSTR2SSTR5SSTR3
Somatostatin Receptor Ligand SCHEMBL12548326 1.00 SSTR4 (0.83) SSTR4SSTR1SSTR2SSTR5SSTR3
Somatostatin Receptor Ligand SCHEMBL16062971 1.00 SSTR4 (0.83) SSTR4SSTR1SSTR2SSTR5SSTR3
Somatostatin SCHEMBL21361053 1.00 SSTR4 (0.83) SSTR4SSTR1SSTR2SSTR5SSTR3
Somatostatin Receptor Ligand SCHEMBL3839184 1.00 SSTR4 (0.83) SSTR4SSTR1SSTR2SSTR5SSTR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100323963-A1 CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF AETERNA ZENTARIS GMBH (DE) 2010-12-23 US claimed
US-20100317580-A1 CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF AETERNA ZENTARIS GMBH (DE) 2010-12-16 US claimed
CN-101578287-A Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazoles derivatives, process for their preparation and their use AETERMA ZENTARIS GMBH (DE) 2009-11-11 CN claimed
EP-2066679-A1 CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF AEterna Zentaris GmbH (DE) 2009-06-10 EP claimed
US-20080090758-A1 CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF AETERNA ZENTARIS GMBH (DE) 2008-04-17 US claimed
EP-1900742-A1 Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof AEterna Zentaris GmbH (DE) 2008-03-19 EP claimed
WO-2008028934-A1 CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF AETERNA ZENTARIS GMBH (DE) 2008-03-13 WO claimed
US-12466851-B2 Manufacture of disulfide bonded peptides BACHEM HOLDING AG (CH) 2025-11-11 US disclosed
US-20220213139-A1 MANUFACTURE OF DISULFIDE BONDED PEPTIDES BACHEM HOLDING AG (CH) 2022-07-07 US disclosed
EP-3956343-A1 MANUFACTURE OF DISULFIDE BONDED PEPTIDES Bachem Holding AG (CH) 2022-02-23 EP disclosed
CN-114026107-A Production of disulfide peptides 巴克姆股份公司 2022-02-08 CN disclosed
US-11033642-B2 Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy UNIVERSITAT ZURICH (CH) 2021-06-15 US disclosed
WO-2020212477-A1 MANUFACTURE OF DISULFIDE BONDED PEPTIDES BACHEM HOLDING AG (CH) 2020-10-22 WO disclosed
CN-101578287-A Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazoles derivatives, process for their preparation and their use AETERMA ZENTARIS GMBH (DE) 2009-11-11 CN disclosed
EP-2066679-A1 CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF AEterna Zentaris GmbH (DE) 2009-06-10 EP disclosed
US-20080090758-A1 CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF AETERNA ZENTARIS GMBH (DE) 2008-04-17 US disclosed
EP-1900742-A1 Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof AEterna Zentaris GmbH (DE) 2008-03-19 EP disclosed
WO-2008028934-A1 CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF AETERNA ZENTARIS GMBH (DE) 2008-03-13 WO disclosed
US-6852688-B2 Compositions for treating diabetic retinopathy and methods of using same UNIVERSITY OF FLORIDA (US) 2005-02-08 US disclosed
US-20020045569-A1 Compositions for treating diabetic retinopathy and methods of using same FLORIDA, UNIVERSITY OF 2002-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11033642-B2 Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy AOC1, XDH, FOLR1 SSTR4 875/4885SSTR1 280/4885SSTR2 607/4885
US-20100323963-A1 CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF EPCAM, CD99, PTMS SSTR4 125/4885SSTR1 541/4885SSTR2 833/4885
US-20100317580-A1 CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF EPCAM, CD99, PTMS SSTR4 125/4885SSTR1 541/4885SSTR2 833/4885
US-20080090758-A1 CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF EPCAM, CD99, PTMS SSTR4 125/4885SSTR1 541/4885SSTR2 833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.